Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals.
Pfizer's controversial smoking-cessation drug Chantix will continue to be stuck with a black-box warning label at least until late next year, assuming the U.S. Food and Drug Administration follows the recommendations of its experts.
The acquisition of dialysis company Gambro last September continues to fuel Baxter International's sales growth as it preps to spin off its biopharma division in 2015. But despite some stop-gap measures, it's not likely that Baxter will actually be able to meet the demand for its dialysis products until additional manufacturing capacity opens up in 2016.
FDA staffers aren't as impressed with new safety data on Chantix as Pfizer wants them to be. In briefing documents filed in advance of Thursday's advisory committee meeting, reviewers say the stop-smoking remedy should keep its black-box warning about potential psychiatric side effects.
Pfizer's pipeline could use a big approval, and it may have one coming in palbociclib.
Pfizer has picked up a priority review designation for its closely watched cancer drug palbociclib, potentially slicing four months off the review timeline for a therapy that is being hustled along at an accelerated rate.
Accenture has joined with some big names for its R&D analytics platform. Eisai, Merck and Pfizer have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and Oracle.
Hoping to boost its chances of FDA approval early next year, Pfizer has unveiled results from a Phase II clinical trial for its meningitis B vaccine, showing that the jab is safe and effective in adolescents when given alongside a licensed vaccine for human papillomavirus.
Just as a federal judge says it's time to close the books on the Chantix litigation that's been moving through her Alabama court, Pfizer is preparing for another kind of fight over the drug. The company has been building its case for the FDA to clear the black-box warning off the stop-smoking drug's label, but patient groups are now petitioning the agency to add more heft to that warning instead.
Pfizer is no stranger to controversy when it comes to Viagra advertising. So a fresh round of criticism aimed at its latest campaign may not be a surprise--but in the age of social media, the critics aren't just telling their friends or writing angry letters. They're complaining to the online universe.